Tags

Type your tag names separated by a space and hit enter

Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease.

Abstract

Postmortem studies have associated Alzheimer's disease (AD) with regionally increased oxidative damage to brain. Lacking, however, is a specific marker of oxidative damage to brain that may be measured during life. We tested the hypothesis that cerebrospinal fluid (CSF) concentrations of F2-isoprostanes (F2-IsoPs), stable products of arachidonate peroxidation, are increased in CSF of AD patients. CSF from lateral ventricles (VF) was analyzed from 11 AD patients and 11 control subjects who participated in a rapid autopsy program. VF F2-IsoP concentrations were significantly elevated in AD patients compared with control subjects (72 +/- 7 vs 46 +/- 4 pg/ml) and were significantly linearly correlated with brain weight (-0.3 pg/ml/g, r2 = 0.32). These results suggest that quantification of CSF F2-IsoP concentrations may provide a useful biomarker of central nervous system oxidative damage in AD.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Pathology, and Center for Molecular Neurosciences, Vanderbilt University Medical Center, Nashville, TN 37232, USA.

    , ,

    Source

    Annals of neurology 44:3 1998 Sep pg 410-3

    MeSH

    Aged
    Aged, 80 and over
    Alzheimer Disease
    Biomarkers
    Dinoprost
    Female
    Humans
    Male

    Pub Type(s)

    Journal Article
    Research Support, U.S. Gov't, P.H.S.

    Language

    eng

    PubMed ID

    9749613

    Citation

    Montine, T J., et al. "Cerebrospinal Fluid F2-isoprostane Levels Are Increased in Alzheimer's Disease." Annals of Neurology, vol. 44, no. 3, 1998, pp. 410-3.
    Montine TJ, Markesbery WR, Morrow JD, et al. Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Ann Neurol. 1998;44(3):410-3.
    Montine, T. J., Markesbery, W. R., Morrow, J. D., & Roberts, L. J. (1998). Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Annals of Neurology, 44(3), pp. 410-3.
    Montine TJ, et al. Cerebrospinal Fluid F2-isoprostane Levels Are Increased in Alzheimer's Disease. Ann Neurol. 1998;44(3):410-3. PubMed PMID: 9749613.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. AU - Montine,T J, AU - Markesbery,W R, AU - Morrow,J D, AU - Roberts,L J,2nd PY - 1998/9/28/pubmed PY - 2001/3/28/medline PY - 1998/9/28/entrez SP - 410 EP - 3 JF - Annals of neurology JO - Ann. Neurol. VL - 44 IS - 3 N2 - Postmortem studies have associated Alzheimer's disease (AD) with regionally increased oxidative damage to brain. Lacking, however, is a specific marker of oxidative damage to brain that may be measured during life. We tested the hypothesis that cerebrospinal fluid (CSF) concentrations of F2-isoprostanes (F2-IsoPs), stable products of arachidonate peroxidation, are increased in CSF of AD patients. CSF from lateral ventricles (VF) was analyzed from 11 AD patients and 11 control subjects who participated in a rapid autopsy program. VF F2-IsoP concentrations were significantly elevated in AD patients compared with control subjects (72 +/- 7 vs 46 +/- 4 pg/ml) and were significantly linearly correlated with brain weight (-0.3 pg/ml/g, r2 = 0.32). These results suggest that quantification of CSF F2-IsoP concentrations may provide a useful biomarker of central nervous system oxidative damage in AD. SN - 0364-5134 UR - https://www.unboundmedicine.com/medline/citation/9749613/Cerebrospinal_fluid_F2_isoprostane_levels_are_increased_in_Alzheimer's_disease_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0364-5134&date=1998&volume=44&issue=3&spage=410 DB - PRIME DP - Unbound Medicine ER -